Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adorcal CC is a nutritional supplement developed by Adorshea Bioceutics, formulated to address calcium deficiency and support overall bone health. It is a combination product containing calcium citrate, magnesium hydroxide, zinc sulfate, and cholecalciferol (Vitamin D3). Calcium citrate serves as a highly bioavailable source of elemental calcium, which is essential for bone mineralization, muscle contraction, and nerve signaling. Cholecalciferol acts as an agonist at the Vitamin D receptor, facilitating the intestinal absorption of calcium and maintaining phosphate homeostasis. Magnesium and zinc are included as essential minerals that act as enzymatic cofactors in bone formation and remodeling processes. The supplement is primarily indicated for the prevention and treatment of osteoporosis, osteomalacia, and other conditions associated with mineral deficiencies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium citrate + magnesium hydroxide + zinc sulfate + cholecalciferol.